Merck blood clot drug in limbo after mixed results

.

Merck blood clot drug in limbo after mixed results

On Saturday, drug-maker Merck & Co provided details about the last month-announced results of the tests of its experimental blood thinner `vorapaxar', revealing that despite the impressive effectiveness of the blood clot drug in bringing about a significant reduction in cardio vascular incidents in heart patients, worrisome bleeding was also witnessed in people who had suffered a stroke.

According to Merck, while the experimental drug, when combined with standard care, proved effective in bringing down the instances of cardio vascular events in heart patients, it also led to increased bleeding in some patients.

When Merck presented limited data from the study in February this year, the company had said that vorapaxar was proving to be an advantageous drug for heart patients. However, the drug-maker has now revealed that patients who had been administered vorapaxar were also experiencing excessive bleeding.

The Merck revelation, based on the results of the biggest heart-drug studies conducted thus far, implies that the vorapaxar blood clot preventer has shown mixed results; and has thus led to concerns whether the drug-maker will go ahead and seek regulatory approval for the drug.

Noting that the vorapaxar trial shows that there is "clearly a tradeoff here between the protective benefit and the risk of bleeding," Dr. David Morrow - who is a cardiologist from Brigham & Women's Hospital in Boston, and the leader of the trial - said: "Should the drug be approved, he said the challenge for doctors would be to withhold it from patients at likely higher bleeding risk."


Latest News

Report: Stock conditions for new iPhones at Apple retail stores will improve by
Apple’s new ‘macOS Sierra’ version brings Siri to desktop; unfolds several other
SquareTrade conducts dunk/drop tests on iPhone 7, iPhone 7 Plus, Galaxy Note 7
Samsung sued over exploded Galaxy Note 7 handset
Only 13% US Galaxy Note 7 users have exchanged their potentially explosive hands
Uber’s self-driving cars hit Pittsburg roads under a test program
Phil Schiller: Removal of headphone jack marks Apple’s desire for technological
Samsung, CPSC ask Galaxy Note 7 owners to stop using their handsets
Analyst: iPhone 7 will be packaged with EarPods which use Lightning connector
Spacecom may seek $50M or free flight from SpaceX to cover the cost of now-destr
Alphabet is shifting some Nest engineers to Google
Apple sued by iPhone 6 and iPhone 6 Plus owners affected by ‘Touch Disease’ prob